# US 2014/0275222 A1 · Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275222 A1
- Document ID: US20140275222A1
- Status: Published application
- Kind: A1
- Application number: 14/357,388
- Filed: 2012-11-09
- Published: 2014-09-18
- Earliest claimed: 2011-11-10
- Assignees: Shire Human Genetic Therapies, Inc.; University of Kentucky
- Applicants: Shire Human Genetic Therapies, Inc.; University of Kentucky
- Inventors: Stefan Stamm; Manli Shen; Serene Josiah
- Web page: https://patentgrep.com/patent/US20140275222A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3521: Methyl
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides, among other things, oligonucleotide modulators of human 5′-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.

## Claims

### Claim 1

An antisense oligonucleotide of 10-50 nucleotides in length comprising a sequence that permits specific hybridization to a target region of a human 5′-HT2C receptor (HTR2C) pre-mRNA under stringent conditions, wherein the target region comprises a nucleotide sequence 5′ UUGGCCAUAAGAAUUGCAGCGGCUAUGCUCAAUACU 3′ (SEQ ID NO: 1) and further wherein the stringent conditions comprise 50% formamide with 1 mg heparin at 42° C. with hybridization carried out overnight and a wash in 0.2×SSC at 65° C. for 15 minutes.

### Claim 2 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the sequence permits specific hybridization to nucleotides 1-18 of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the sequence permits specific hybridization to nucleotides 10-27 of SEQ ID NO: 1.

### Claim 4 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the sequence permits specific hybridization to nucleotides 19-36 of SEQ ID NO: 1.

### Claim 5 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the sequence permits specific hybridization to nucleotides 19-30 of SEQ ID NO: 1.

### Claim 6

An antisense oligonucleotide of 10-50 nucleotides in length comprising a sequence at least 70% identical to 10 or more contiguous nucleotides that appear in 5′ AGUAUUGAGCAUAGCCGCUGCAAUUCUUAUGGCCAA 3′ (SEQ ID NO: 15).

### Claim 7 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the sequence is at least 70% identical to any of 5′ UGCAAUUCUUAUGGCCAA 3′ (SEQ ID NO:8), 5′ CAUAGCCGCUGCAAUUCU 3′ (SEQ ID NO:4), 5′ AGUAUUGAGCAUAGCCGC 3′ (SEQ ID NO:5), or 5′ GAGCAUAGCCGC 3′ (SEQ ID NO:7).

### Claim 8 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the sequence is selected from the group consisting of 5′ UGCAAUUCUUAUGGCCAA 3′ (SEQ ID NO:8), 5′ CAUAGCCGCUGCAAUUCU 3′ (SEQ ID NO:4), 5′ AGUAUUGAGCAUAGCCGC 3′ (SEQ ID NO:5), or 5′ GAGCAUAGCCGC 3′ (SEQ ID NO:7), and combination thereof.

### Claim at position 9

9-14. (canceled)

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the antisense oligonucleotide of claim 1, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A method of modulating human 5′-HT2C receptor (HTR2C) activity in a cell, the method comprising delivering an antisense oligonucleotide of claim 1 to the cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cell is a neuron.

### Claim 18 (depends on 17)

The method of claim 17, wherein the neuron is in the hypothalamus region of the brain.

### Claim 19

(canceled)

### Claim 20 (depends on 19)

The method of claim 19, wherein the antisense oligonucleotide is administered at a concentration greater than 5 nM.

### Claim 21 (depends on 1)

A method of reducing food consumption in a subject comprising administering to a subject in need of treatment an antisense oligonucleotide of claim 1.

### Claim 22 (depends on 1)

A method of treating hyperphagia comprising administering to a subject in need of treatment an antisense oligonucleotide of claim 1.

### Claim 23 (depends on 1)

A method of treating obesity comprising administering to a subject in need of treatment an antisense oligonucleotide of claim 1.

### Claim 24 (depends on 1)

A method of treating Prader-Willi syndrome comprising administering to a subject in need of treatment an antisense oligonucleotide of claim 1.

### Claim at position 20

25-26. (canceled)

### Claim 27 (depends on 1)

A kit comprising an antisense oligonucleotide of claim 1; and tools for administration to the brain of a mammal.
